

File No: BIO/CT/23/000057
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

From:

The Drugs Controller General, India
Directorate General of Health Services,

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated: 18.09.2023

To,

M/s Lupin Limited, Biotech Division,
Gat No. 1156, 1157, 1158, 1159 and 1160,
Village Ghotawade, Taluka Mulshi,
Pune, Maharashtra (India) – 412115

Subject: Application for grant of permission to conduct pharmacokinetic study titled – “An open label, balanced, randomized, single-dose, two treatment, two-sequence, four-period, crossover, fully-replicate, reference scaled comparative pharmacokinetics study of Lupin’s Pegfilgrastim on body injector filled with Peg-filgrastim prefilled syringe solution for subcutaneous injection (Test) to deliver 6mg/0.6 mL with Lupin’s Peg-filgrastim solution in a single-dose prefilled syringe for manual subcutaneous injection(Reference) to deliver 6 mg/0.6 mL in Healthy, Adult, Human Subjects” vide protocol no. LBC-P-023-23 version 00 dated 06.04.2023” - regarding

Ref.: Your Application No. BIO/CT04/FF/2023/35976 dated 19-Apr-2023

Sir,

With reference to your Application No.: BIO/CT04/FF/2023/35976 dated 19-Apr-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
- (III) Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
- (IV) Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (V) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking

approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

- (VI) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (VII) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VIII) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (IX) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (X) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (XI) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (XII) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XIII) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIV) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XV) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XVI) The laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XVII) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective,

design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(XVIII) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(XIX) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

Yours faithfully,

RAJEEV SINGH (Dr. Rajeev Singh Raghuvanshi)
RAGHUVANS Central Licensing Authority
HI

Digitally signed by RAJEEV SINGH
RAGHUVANS
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANS,
2.5.4.2769041015a06564fe67f54b765db1eb,
postalCode=600034, st=TAMIL NADU,
serialNumber=657F5E47D940985D8F03BDC90
2D0E1FE73CFA12A1A126EA94FA5701124A19
013, cn=RAJEEV SINGH RAGHUVANS
Date: 2023.09.18 16:37:57 +05'30'

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits **M/s Lupin Limited, Biotech Division, Gat No. 1156, 1157, 1158, 1159 and 1160, Village Ghotawade, Taluka Mulshi, Pune, Maharashtra (India) – 412115**, to conduct clinical trial of the new drug or investigational new drug study titled “An open label, balanced, randomized, single-dose, two treatment, two-sequence, four-period, crossover, fully-replicate, reference scaled comparative pharmacokinetics study of Lupin’s Pegfilgrastim on body injector filled with Peg-filgrastim prefilled syringe solution for subcutaneous injection (Test) to deliver 6mg/0.6 mL with Lupin’s Peg-filgrastim solution in a single-dose prefilled syringe for manual subcutaneous injection(Reference) to deliver 6 mg/0.6 mL in Healthy, Adult, Human Subjects” vide protocol no. LBC-P-023-23 version 00 dated 06.04.2023” in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 18.09.2023

RAJEEV SINGH RAGHUVANSHI
Drugs Controller General (India)
Central Licensing Authority
HI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=RAJEEV SINGH RAGHUVANSHI, o=RAJEEV SINGH
RAGHUVANSHI, ou=RAJEEV SINGH RAGHUVANSHI,
c=IN, email=rajeev.singh.raghuvanshi@cdsco.gov.in,
serialNumber=65715247D940963D81380C622D0
E1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.09.18 16:38:27 +05'30'

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug	Pegfilgrastim 6 mg/0.6 mL (r-DNA origin) solution for injection		
Therapeutic class	Leukocyte growth colony stimulating factor		
Dosage form:	Solution for injection presented in a pre-filled syringe (PFS) to be used for administration by on body injector (OBI).		
Composition:	Name of Ingredient	Qty. per PFS	Function
	Pegfilgrastim IH	6 mg	Active pharmaceutical Ingredient
	Sorbitol USP-NF, IP, Ph. Eur., BP and JP	30 mg	Tonicity modifier
	*Glacial acetic acid USP, IP, Ph. Eur., BP and JP	0.77 mg	Buffering agent
	#Sodium acetate Trihydrate USP, IP, Ph.Eur., BP and JP	0.11 mg	Buffering agent
	Polysorbate 20 USP-NF, IP, Ph.Eur. and BP	0.02 mg	Stabilizer
	Water for injection USP, IP, Ph. Eur, BP and JP	q.s. to 0.6 ml	Diluent
	*Acetate content: 0.80 mg/0.6 mL (1.378 mg/mL) #Sodium content: 0.02 mg/0.6 mL (0.033 mg/mL)		
Indications:	To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.		

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Lupin Bioresearch Center, Sai Trinity, A Wing,	Lifepoint Research- Ethics Committee, Lifepoint	Dr. Chintan Shaileshbhai

	Survey No. 146/2/1B, Pashan, Pune – 411021	Multispeciality Hospital Pvt. Ltd., 145/1, Mumbai- Bangalore Highway, Near Hotel Sayaji, Wakad, Pune- 411057, Maharashtra, India. <u>EC Reg. No.</u> <u>ECR/751/Inst/MH/2015/RR-</u> <u>18</u>	
--	-----------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

